Listing analysis and research matching BMS:
Bristol Myers-Squibb expands partnerships
In April 2007 Bristol-Myers Squibb Co entered two collaborations with Pfizer Inc in the field of anticoagulants and metabolic diseases worth up to US$1 billion. The deal comes close on the heals of another deal with AstraZeneca in January 2007 worth up to US$1 billion. Such deals are part of an interesting partnering strategy currently being pursued by Bristol Myers-Squibb to reduce the costs of marketing and sales and concentrate its efforts on discovery and early development. The fact that companies like Pfizer and AstraZeneca are beginning to invest such huge sums of money in the discovery and early development efforts of companies like Bristol Myers-Squibb shows how desperate the competition is for big pharmaceutical companies to fill their product pipelines.
